EAACI Congress 2024
BackAllergen immunotherapy 2
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Analytical testing of PQ Grass allergoid drug product using antibodies
12:00
Assessing specific pro-catabolic mediators (SPMs) as Innovative Biomarkers in Allergen Immunotherapy: Monitoring Treatment Efficacy
12:00
Can serum biomarkers predict long-term control of allergic rhinitis after immunotherapy?
12:00
Clinical evaluation of an immunotherapy treatment with Vespa velutina venom in allergic patients. Results from a prospective multicenter Study: W-STING Study
12:00
Early inflammatory reactions in mice after immunotherapy with an allergen microcrystalline tyrosine adsorbate
12:00
First-in-class biologic to treat House dust mite allergy
12:00
In vitro safety profile and tolerogenic response with depigmented and polymerized extracts in polyallergic patients to grass pollen and cat epithelia
12:00
Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children
12:00
Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates allergic response in a murine model of allergic rhinitis
12:00
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
12:00
Safety and tolerance response of a two day rush protocol treatment in immunotherapy using purified Apis mellifera dry Honeybee venom extract
12:00
Subcutaneous allergen-specific immunotherapy- Safety and risk factors of adverse effects. Data from a tertiary allergy centre
12:00
The importance of detecting co-sensitization in patients with seasonal allergic rhinitis
12:00
The utility of basophil activation testing in honey bee venom allergy diagnosis and venom immunotherapy
12:00
Сytokine profiles in patients with allergic rhinitis during allergen-specific immunotherapy with and without added vitamin D
